Shattuck Labs, Inc. (STTK)
NASDAQ:STTK
Want to see STTK full AI Analyst Report?
STTK Stock Chart & Stats
$7.53
>-$0.01(-0.39%)
At close: 4:00 PM EST
$7.53
>-$0.01(-0.39%)
Day’s Range― - ―
52-Week Range$0.71 - $8.33
Previous CloseN/A
Volume43.14K
Average Volume (3M)942.71K
Market Cap
$447.34M
Enterprise Value$139.53M
Total Cash (Recent Filing)$90.42M
Total Debt (Recent Filing)$2.89M
Price to Earnings (P/E)―
Beta2.17
Next Earnings
Aug 06, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.63
Shares Outstanding90,372,390
10 Day Avg. Volume1,613,114
30 Day Avg. Volume942,711
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.08
Price to Sales (P/S)253.99
P/FCF Ratio-6.36
Enterprise Value/Market Cap0.31
Enterprise Value/Revenue139.53
Enterprise Value/Gross Profit-170.16
Enterprise Value/Ebitda-3.02
Forecast
1Y Price Target
$15.80Price Target Upside109.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.51
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline Progress (SL-325 Phase 1 → Phase 2b)Human Phase 1 data demonstrating durable target blockade, low immunogenicity and a clean safety profile materially de-risks SL-325. A planned Phase 2b in Crohn’s establishes a clear clinical pathway and increases the program’s probability of translating into long-term commercial or partner value.
Low Financial LeverageMinimal debt gives Shattuck Labs durable financial flexibility to fund R&D decisions without large interest burdens. Low leverage preserves strategic optionality for partnering, acquisitions, or selective financing over the next several quarters while advancing clinical programs.
Recent Financing And Warrant Exercises Bolstering CashFresh proceeds and an upsized offering materially extend runway to support RECEPTIVE-CD1 and SL-846 development. Improved near-term funding reduces immediate liquidity pressure and allows program execution and regulatory filings without relying solely on dilutive emergency financings.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow indicate the company continues to consume capital to fund operations. Even with recent fundraising, continued burn at this scale increases the probability of further financings, which can dilute existing holders and constrain long-term R&D plans.
Minimal Revenue And Large Net LossesVery low revenue versus large losses shows the business lacks a sustainable commercial engine and remains entirely development-stage. Persistent negative margins mean value depends on clinical success; setbacks would materially impair the company’s ability to self-fund programs and deliver long-term returns.
Eroding Equity Base And Negative ROEMaterial erosion of equity reduces the capital cushion available to absorb further losses and heightens reliance on external financing. Strongly negative ROE signals that deployed capital has not generated returns, raising structural concerns about capitalization unless clinical progress reverses the trend.
Shattuck Labs News
STTK FAQ
What was Shattuck Labs, Inc.’s price range in the past 12 months?
Shattuck Labs, Inc. lowest stock price was $0.71 and its highest was $8.33 in the past 12 months.
What is Shattuck Labs, Inc.’s market cap?
Shattuck Labs, Inc.’s market cap is $447.34M.
When is Shattuck Labs, Inc.’s upcoming earnings report date?
Shattuck Labs, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 47 days.
How were Shattuck Labs, Inc.’s earnings last quarter?
Shattuck Labs, Inc. released its earnings results on May 07, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.138 by $0.008.
Is Shattuck Labs, Inc. overvalued?
According to Wall Street analysts Shattuck Labs, Inc.’s price is currently Undervalued.
Does Shattuck Labs, Inc. pay dividends?
Shattuck Labs, Inc. does not currently pay dividends.
What is Shattuck Labs, Inc.’s EPS estimate?
Shattuck Labs, Inc.’s EPS estimate is -0.13.
How many shares outstanding does Shattuck Labs, Inc. have?
Shattuck Labs, Inc. has 90,372,390 shares outstanding.
What happened to Shattuck Labs, Inc.’s price movement after its last earnings report?
Shattuck Labs, Inc. reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.138. Following the earnings report the stock price went down -6.287%.
Which hedge fund is a major shareholder of Shattuck Labs, Inc.?
Currently, no hedge funds are holding shares in STTK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shattuck Labs Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.80 (109.83% Upside)
$15.80 (109.83% Upside)
Blogger Sentiment
Bullish
STTK Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $250.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 21.2%
Last 30 Days ▲ 30.2%
Last 30 Days ▲ 30.2%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
408.21%
12-Months-Change
Fundamentals
Return on Equity
-60.73%
Trailing 12-Months
Asset Growth
32.34%
Trailing 12-Months
Company Description
Shattuck Labs, Inc.
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
STTK Stock 12 Month Forecast
Average Price Target
$15.80
▲(109.83% Upside)
Technical Analysis
Ownership Overview
24.57% Insiders
12.22% Mutual Funds
44.31% Other Institutional Investors
16.07% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---